Cargando…

Giant plasma cells with multiple immature nuclei in a young woman with newly diagnosed multiple myeloma

BACKGROUND: Multiple myeloma with giant multinucleated plasma cells is a very rare entity and mostly reported cases are dated. This plasma cell morphology has been observed after monoclonal antibody treatments, such as daratumumab, and patients have experienced a worse prognosis with partial respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giudice, Valentina, De Novellis, Danilo, Guariglia, Roberto, Fumo, Rosalba, Ciancia, Giuseppe, Serio, Bianca, Selleri, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757013/ https://www.ncbi.nlm.nih.gov/pubmed/36397299 http://dx.doi.org/10.1002/jcla.24782

Ejemplares similares

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)

Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review
por: Manzo, Paola, et al.
Publicado: (2023)

Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
por: De Novellis, Danilo, et al.
Publicado: (2022)

P1544: IMPACT OF SARS-COV 2 INFECTION, IN TREATED NHL-B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE
por: Pezzullo, Luca, et al.
Publicado: (2023)

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A
por: De Novellis, Danilo, et al.
Publicado: (2022)

P1531: TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE
por: Pezzullo, Luca, et al.
Publicado: (2023)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022)

Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia
por: Giudice, Valentina, et al.
Publicado: (2022)

Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient
por: Serio, Bianca, et al.
Publicado: (2022)

PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
por: De Novellis, D., et al.
Publicado: (2022)

A Rare Immune-Related Mesenteric and retroperitoneal serositis in a Multi-Refractory Hodgkin Lymphoma Patient Successfully Treated with Chylolymphostatic Surgery
por: D’Addona, Matteo, et al.
Publicado: (2023)

Flower-Like Plasma Cell Nuclei in Multiple Myeloma
por: Sall, Abibatou, et al.
Publicado: (2021)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Post-therapy B Regulatory Cells Might early Predict Relapse in Hodgkin Lymphoma
por: Giudice, Valentina, et al.
Publicado: (2022)

Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
por: Giudice, Valentina, et al.
Publicado: (2016)

Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation
por: Parente, Roberta, et al.
Publicado: (2023)

Hodgkin Lymphoma and Hairy Cell Leukemia Arising from Chronic Lymphocytic Leukemia: Case Reports and Literature Review
por: D’Addona, Matteo, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Giant retrocrural plasmacytoma as a relapse of multiple myeloma
por: Feki, Afef, et al.
Publicado: (2022)

Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma
por: Chen, Yuxi, et al.
Publicado: (2018)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

67 kDa laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach?
por: Montuori, Nunzia, et al.
Publicado: (2016)

A case of multiple myeloma with markedly straight lines or curved deep groove nuclei
por: He, Chang, et al.
Publicado: (2021)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma: Erratum
Publicado: (2016)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mfifu9mhdpa1jrrlfldtunrtih